Skip to content
10-Q

Quarterly Report

SYNAGEVA BIOPHARMA CORP

0001193125-14-177263

← back to feed
Filed
May 1, 2014 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2014 · Apr 25, 2014 33.02M sh
Short Term Investments Q1 2014 · Mar 31, 2014 $422.89M
Short Term Investments Q1 2014 · Dec 31, 2013 $346.6M
Stockholders Equity Q1 2014 · Mar 31, 2014 $601.09M
Stockholders Equity Q1 2014 · Dec 31, 2013 $430.2M
Current Liabilities Q1 2014 · Mar 31, 2014 $17.19M
Current Liabilities Q1 2014 · Dec 31, 2013 $13.92M
Total Liabilities Q1 2014 · Mar 31, 2014 $22.01M
Total Liabilities Q1 2014 · Dec 31, 2013 $17.75M
Current Assets Q1 2014 · Mar 31, 2014 $585.59M
Current Assets Q1 2014 · Dec 31, 2013 $416.72M
Total Assets Q1 2014 · Mar 31, 2014 $623.1M
Total Assets Q1 2014 · Dec 31, 2013 $447.95M
Shares Diluted Q1 2014 · Mar 31, 2013 26.83M sh
Capex Q1 2014 · Mar 31, 2013 $2.41M
Cash And Equivalents Q1 2014 · Mar 31, 2013 $53.76M
Cash And Equivalents Q1 2014 · Dec 31, 2012 $23.88M
Eps Diluted Q1 2014 · Mar 31, 2013 −$0.54
Eps Basic Q1 2014 · Mar 31, 2013 −$0.54
Sga Expense Q1 2014 · Mar 31, 2013 $5.65M
Rd Expense Q1 2014 · Mar 31, 2013 $13.34M
Net Income Q1 2014 · Mar 31, 2013 −$14.48M
Operating Income Q1 2014 · Mar 31, 2013 −$14.57M
Revenue Q1 2014 · Mar 31, 2013 $5.12M